The abstract is read at the publisher; the summary is JClub's.
TMM-based classification is the only independent prognostic factor in 366 neuroblastoma patients, with HRs of 6.4 for EFS and 29.4 for OS.
- Why it matters: Neuroblastoma’s clinical heterogeneity makes precise risk stratification essential to avoid overtreatment, especially among current non-high-risk patients.
- What they did: The study evaluated telomere maintenance mechanisms against standard-of-care variables and compared TMM with chromosomal copy-number and gene expression classifiers using multivariable models in 366 patients.
- The result: In both test (n = 116) and validation (n = 143) sets, TMM and gene expression separated non-high-risk patients into excellent versus adverse EFS and OS, and TMM outperformed the other molecular classifiers (P < .001).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.